Hints and tips:
...Before Alere, Mr Nawana spent more than 15 years at Johnson & Johnson, including time as president of its DePuy Synthes spine business....
...It has not done a big deal since it bought Synthes in 2012. And mountains of debt could be added to get a deal done. The company has a rare AAA credit rating....
...It also reported restructuring linked to its acquisition of Synthes of Switzerland, finalised in 2012....
...Johnson & Johnson, the world’s largest healthcare company, started to see the benefits of last year’s acquisition of Synthes, as growing medical device sales boosted its third-quarter revenues....
...In the second quarter, J&J was hit by costs related to the closing of its deal last year to acquire Synthes, the medical device company....
...Johnson & Johnson shares rose 1.3 per cent to $69.55 after the world’s largest healthcare company reported solid growth in revenues, due to sales from its medical device unit Synthes....
...S&P Capital IQ reiterated its “buy” rating for Johnson & Johnson, saying that the company’s acquisition of medical device producer Synthes had been given regulatory approval....
...People familiar with the situation said officials at SIX, the Swiss stock exchange, were examining a spike in Synthes’ shares before the deal was announced....
...Most subsequent deals have been more targeted on particular products or regions, such as Sanofi’s purchase of Genzyme in 2011, which specialises in “orphan diseases”; Johnson & Johnson’s purchase of Synthes...
...Johnson & Johnson has agreed a $21.3bn takeover of Switzerland’s Synthes to create the world’s leading orthopaedic devices group, reports the FT....
...Shares in Synthes rose more than 12 per cent in European markets on Monday, on speculation the deal could value it at $20bn....
...Some $516.1bn worth of deals was announced in the second quarter with Johnson & Johnson’s $21.2bn offer to acquire Swiss-based Synthes being the largest for the period....
...Working backwards, J&J is offering about 22 per cent more than Synthes’ undisturbed market capitalisation....
...The net cost to J&J will be about $19.3bn, given that Synthes has about $2bn in cash....
...Fracture a bone anywhere in the world and the odds are good that Synthes will supply the materials to mend it....
...If Synthes is bought by Johnson & Johnson, it will dispel years of speculation about the plans of Hansjörg Wyss, the group’s publicity-shy guiding light....
...Credit Suisse advised Synthes. J&J was advised by Goldman Sachs....
...In the 1970s, a third group, Synthes USA, became involved. Over the past decade, the groups involved consolidated, with Hansjörg Wyss, the Swiss entrepreneur behind Synthes USA, becoming dominant....
...The biggest announced deal was, of course, the $21.5bn acquisition of Synthes by Johnson & Johnson....
...Consolidation is intensifying, including Johnson & Johnson’s recent $21bn purchase of Synthes of Switzerland....
...The press release: In response to market speculation, Synthes, Inc....
...Even Johnson & Johnson may still have appetite, given the large ex-US cash pile it retains – best used abroad for tax reasons – in spite of its takeover of Synthes....
...Investors and analysts were hoping to learn more about J&J’s takeover talks with Synthes, the Swiss medical device maker that acknowledged on Monday that discussions about a combination were taking place...
...Synthes controls about 50 per cent of the market for trauma devices. As with J&J, Synthes has had its share of problems....
International Edition